Eupatilin
(Synonyms: 异泽兰黄素) 目录号 : GN10511
A flavonoid with diverse biological activities
Cas No.:22368-21-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
Cell viability is detected using a MTT assay. In brief, after treatment, the medium is replaced with fresh medium containing 0.5 mg/mL MTT for 4 h at 37°C. Then, the medium is gently aspirated and 150 μL of DMSO is added to each well to solubilize the formazan crystals. The absorbance is measured at 450 nm by a microplate reader. The relative cell viability is defined as the absorbance of treated wells divided by that of the control[3]. |
|
Animal experiment: |
Six-week-old female Balb/c mice are housed under conditions of controlled temperature (23 ± 2 °C), humidity (55 ± 5%), and 12 h light/dark cycles (06:00-18:00 h light, 18:00-06:00 dark). Briefly, Balb/c mice are sensitized on day −7 by a single application of 20 μL of 1.0% oxazolone in a mixture of acetone and olive oil (4:1) to the inner and outer surface of both ears. On day 0, the mouse ears are challenged with 20 μL of 0.1% oxazolone at 2-day intervals for 4 weeks post-sensitization. The mice are treated with the indicated concentrations of Eupatilin (1.5% or 3.0%) twice a day for 4 weeks. The control group is treated with vehicle alone (acetone and olive oil [4:1]). After 3 weeks, the mice are sacrificed and samples are collected. Ears are stored at −80 °C for RNA isolation and analysis or immediately fixed in 4% formalin for histological analysis[1]. |
|
References: [1]. Jung Y, et al. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514. |
|
Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
Eupatilin is a PPARα agonist. Eupatilin (10, 30, 100 μM) suppresses IL-4 expression and degranulation in RBL-2H3 cells[1]. Eupatilin (50-100 μM) slightly reduces cell viability of HaCaT cells. Eupatilin (10, 30, 50, 100 μM) increases PPARα transactivation and expression in HaCaT cells. Eupatilin (10, 30, 50 μM) also suppresses TNFα-induced MMP-2/-9 expression in HaCaT cells. Furthermore, Eupatilin inhibits TNFα-induced p65 translocation, IκBα Phosphorylation, AP-1 and MAPK signaling via PPARα[2]. Eupatilin (10-50 μM) shows no cytotoxic effects on ARPE19 cells. Eupatilin (10, 25, 50 μM) elevates cell viability from oxidative stress, and inhibits H2O2-induced ROS production in ARPE19 cells. Moreover, Eupatilin (50 μM) inbibits H2O2-induced cells apoptosis and promotes the activation of PI3K/Akt pathway in RPE cells[3].
Eupatilin (1.5% or 3.0%) restores PPARα mRNA expression, and improves atopic dermatitis (AD)-like symptoms in oxazolone-induced Balb/c mice. Eupatilin causes significant decrease in serum IgE, IL-4 levels, oxazolone-induced TNFα, IFNγ, IL-1β, TSLP, IL-33 and IL-25 mRNA expression in oxazolone-induced mice. Eupatilin also increases filaggrin and loricrin mRNA expression in oxazolone-induced mice[1].
References:
[1]. Jung Y, et al. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514.
[2]. Jung Y, et al. Eupatilin with PPARα agonistic effects inhibits TNFα-induced MMP signaling in HaCaT cells. Biochem Biophys Res Commun. 2017 Nov 4;493(1):220-226.
[3]. Du L, et al. Eupatilin prevents H2O2-induced oxidative stress and apoptosis in human retinal pigment epithelial cells. Biomed Pharmacother. 2017 Jan;85:136-140.
| Cas No. | 22368-21-4 | SDF | |
| 别名 | 异泽兰黄素 | ||
| 化学名 | 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one | ||
| Canonical SMILES | COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O)OC)O)OC | ||
| 分子式 | C18H16O7 | 分子量 | 344.32 |
| 溶解度 | ≥ 34.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。